Would be great to see a plan.My assumption has been:p1a - Single...

  1. 4,469 Posts.
    lightbulb Created with Sketch. 4594
    Would be great to see a plan.

    My assumption has been:

    p1a - Single agent dose expansion.

    p1b - Combination dose expansion

    Apparently, we're seeing combo dosing from the outset. This has me wondering what the p1a is for? If the combination dose expansion starts from p1a, then, by the definition of a dose expansion study, a cohort should be receiving the optimum combination dosing. Why would this not have the potential to validate CPACS? Surely the clinical trial strategy is one of the many updates presented at the AGM.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.22
Change
-0.065(5.06%)
Mkt cap ! $211.9M
Open High Low Value Volume
$1.29 $1.29 $1.21 $205.4K 165.5K

Buyers (Bids)

No. Vol. Price($)
1 788 $1.22
 

Sellers (Offers)

Price($) Vol. No.
$1.23 42 1
View Market Depth
Last trade - 16.10pm 24/06/2025 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.